Consensus PHAXIAM Therapeutics S.A.

Equities

PHXM

FR001400K4B1

End-of-day quote Euronext Paris Other stock markets 06:00:00 2024-05-19 pm EDT			5-day change	1st Jan Change
3.055 ^EUR	0.00%		+0.99%	-33.59%

Apr. 15	Phaxiam initiates trial in infective endocarditis	CF
Apr. 15	PHAXIAM Therapeutics Announces Enrolment of First Patient in the Phase 1 Study for the Treatment of Endocarditis Infections Caused by Staphylococcus Aureus	CI

Evolution of the average Target Price on PHAXIAM Therapeutics S.A.

Price target over the last 5 years

History of analyst recommendation changes

f68413ee2b84c2f3752651052798b5.fRxgraK6hnRAVAzBpJ_ADpI28ABc1SBxlkuv3gBJhmM.OE4lz8Xfzj95G1qo9umRRPNiqWQR7RUB4xvMuHE-9zYLSyjOzdCyBiIyNA~0b1f096cf328144b2b2348ac7fe4143b

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

3.04 EUR

Average target price

6.85 EUR

Spread / Average Target

+125.33%

High Price Target

8 EUR

Spread / Highest target

+163.16%

Low Price Target

5.7 EUR

Spread / Lowest Target

+87.50%

Consensus detail

Consensus revision (last 18 months)

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar